Originally published July 29.

NEW YORK (GenomeWeb) – AstraZeneca is exploring the use of liquid biopsy-based companion tests to pick out best responders for its drugs for lung cancer, where acquiring biopsy tissue is particularly challenging for advanced patients.

The drugmaker this week announced two deals, one with Qiagen and another with Roche, to advance liquid biopsy-based companion diagnostics for its marketed non-small cell lung cancer drug Iressa (gefitinib) and the investigational NSCLC agent AZD9291, respectively.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.